Persistence of gadolinium contrast enhancement in CSF: A possible harbinger of gadolinium neurotoxicity?

American Journal of Neuroradiology

Volumn 30, Issue 1, 2009, Pages

  Hui, F K ^a   Mullins, M ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM CHELATE; GADOLINIUM DIMEGLUMINE; UNCLASSIFIED DRUG;

BRAIN DISEASE; CASE REPORT; CEREBROSPINAL FLUID; CONTRAST ENHANCEMENT; DRUG DIFFUSION; HUMAN; LETTER; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING;

BRAIN; CEREBROSPINAL FLUID; CONTRAST MEDIA; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEUROTOXICITY SYNDROMES; NEUROTOXINS; RISK ASSESSMENT;

EID: 58249124572     PISSN: 01956108     EISSN: None     Source Type: Journal    
DOI: 10.3174/ajnr.A1205     Document Type: Letter

References (4)

1. Arsenault TM, King BF, Marsh JW Jr, et al. Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: retrospective analysis of an initial experience. Mayo Clin Proc 1996;71:1150-54
2. Maramattom BV, Manno EM, Wijdicks EF, et al. Gadolinium encephalopathy in a patient with renal failure. Neurology 2005;64:1276-78
3. Rai AT, Hogg JP. Persistence of gadolinium in CSF: a diagnostic pitfall in patients with end-stage renal disease. AJNRAm J Neuroradiol 2001;22:1357-61
4. Arlt S, Cepek L, Rustenbeck HH, et al. Gadolinium encephalopathy due to accidental intrathecal administration of gadopentetate dimeglumine. J Neurol 2007;254:810-12. Epub 2007 Apr 2